@article{leal_decision_nodate,
title = {Decision models of prediabetes populations: a systematic review},
volume = {0},
rights = {This article is protected by copyright. All rights reserved.},
issn = {1463-1326},
url = {https://onlinelibrary.wiley.com/doi/abs/10.1111/dom.13684},
doi = {10.1111/dom.13684},
shorttitle = {Decision models of prediabetes populations},
abstract = {Aims With evidence supporting the use of preventive interventions for prediabetes populations and the use of novel biomarkers to stratify the risk of progression there is a need to evaluate their cost-effectiveness across jurisdictions. Our aim is to summarise and assess the quality and validity of decision models and model-based economic evaluations of populations with prediabetes, evaluate their potential use for the assessment of novel prevention strategies and discuss the knowledge gaps, challenges and opportunities. Materials and methods We searched Medline, Embase, {EconLit} and {NHS} {EED} between 2000 and 2018 for studies reporting computer simulation models of the natural history of individuals with prediabetes and/or used decision models to evaluate the impact of treatment strategies on these populations. Data were extracted following {PRISMA} guidelines and assessed using modelling checklists. Two reviewers independently assessed 50\% of the titles and abstracts to determine whether a full text review was needed. Of these, 10\% was assessed by each reviewer to cross-reference the decision to proceed to full review. Using a standardised form, and double extraction, four reviewers each extracted 50\% of identified studies. Results Twenty-nine published decision models that simulate prediabetes populations were identified. Studies showed large variations in the definition of prediabetes and model structure. The inclusion of complications in prediabetes (n=8) and type 2 diabetes (n=17) health states also varied. A minority of studies simulated annual changes in risk factors (glycaemia, {HbA}1c, blood pressure, {BMI}, lipids) as individuals progressed in the models (n=7) and accounted for heterogeneity amongst individuals with prediabetes (n=7). Conclusions Current prediabetes decision models have considerable limitations in terms of their quality and validity and are not equipped to evaluate stratified strategies using novel biomarkers highlighting a clear need for more comprehensive prediabetes decision models. This article is protected by copyright. All rights reserved.},
issue = {ja},
journaltitle = {Diabetes, Obesity and Metabolism},
author = {Leal, Jose and Morrow, Liam Mc and Kurshid, Waqar and Pagano, Eva and Feenstra, Talitha},
urldate = {2019-03-07},
langid = {english},
keywords = {biomarker, decision model, economic evaluation, prediabetes, stratified treatment, systematic review}
}